KNSA – kiniksa pharmaceuticals, ltd. - class a (US:NASDAQ)
Stock Stats
News
1/15
07:46 am
knsa
Low
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/13
09:03 am
knsa
Medium
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wedbush from $48.00 to $50.00. They now have an "outperform" rating on the stock.
1/12
07:30 am
knsa
Medium
Kiniksa Pharmaceuticals Provides Corporate Update
1/7
04:01 pm
knsa
Low
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
12/2
07:33 pm
knsa
Low
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
10/28/2025
07:30 am
knsa
-7.5%
MISS
7/29/2025
07:30 am
knsa
11.4%
BEAT
4/29/2025
07:30 am
knsa
15.0%
BEAT
2/25/2025
07:30 am
knsa
-3.8%
MISS
1/13
08:50 am
Maintains
Outperform
Outperform
Wedbush
Medium
-6.1%
1/13
08:50 am
Maintains
Outperform
Outperform
Wedbush
Medium
-6.1%
12/2
07:33 pm
Reiterates
Outperform
Wedbush
Low
1.5%
12/2
07:33 pm
Reiterates
Outperform
Wedbush
Low
1.5%
10/29
02:08 pm
Maintains
Buy
Buy
Goldman Sachs
Low
-1.1%
1/14
04:31 pm
knsa
Medium
Form 8-K Kiniksa Pharmaceuticals For: Jan 10
1/12
05:23 pm
knsa
Medium
Form 8-K Kiniksa Pharmaceuticals For: Jan 12
1/9
04:36 pm
knsa
Medium
Form 4 Kiniksa Pharmaceuticals For: Jan 08 Filed by: Ragosa Mark
12/17
04:38 pm
knsa
Low
Form 4 Kiniksa Pharmaceuticals For: Dec 15 Filed by: Quart Barry D
12/17
04:38 pm
knsa
Low
Form 4 Kiniksa Pharmaceuticals For: Dec 15 Filed by: Tessari Eben
Show more
Top News Gainers
11/20 Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis 28.7%
3/31 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation 26.7%
12/10 Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 18.5%
10/28 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus N/A ActVsEst N/A - N/A 11.8%
8/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 6.2%
3/17 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 5.7%
6/7 Form SC 13D/A Kiniksa Pharmaceuticals, Filed by: BAKER BROS. ADVISORS LP 4.4%
3/20 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.2%
8/19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 4.0%
1/13 Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts 3.6%
Top News Decliners
3/17 Form 4 Kiniksa Pharmaceuticals, For: Mar 13 Filed by: Paolini John F. -16.6%
3/10 Form 4 Kiniksa Pharmaceuticals, For: Mar 06 Filed by: Patel Sanj K -10.4%
11/5 Form 10-Q Kiniksa Pharmaceuticals, For: Sep 30 -8.4%
6/11 Form EFFECT Kiniksa Pharmaceuticals, -8.1%
4/22 Form 4 Kiniksa Pharmaceuticals, For: Apr 20 Filed by: Beetham Thomas W. -7.1%
4/29 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.2%
2/14 Form SC 13G Kiniksa Pharmaceuticals, Filed by: AMERIPRISE FINANCIAL INC -5.6%
7/11 Form D/A Kiniksa Pharmaceuticals, -5.2%
4/1 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a $25.00 price target on the stock. -5.2%
10/16 Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3